Loading…

Loading grant details…

Completed H2020 European Commission

Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials

€5.94M EUR

Funder European Commission
Recipient Organization European Organisation for Research and Treatment of Cancer Aisbl
Country Belgium
Start Date Jan 01, 2021
End Date Dec 31, 2025
Duration 1,825 days
Number of Grantees 34
Roles Participant; Coordinator
Data Source European Commission
Grant ID 945052
Grant Description

Measuring and quantifying how a patient feels or functions during treatment is an important endpoint in cancer clinical trials.

It is generally accepted that the collection of PRO data in cancer clinical trials allows the inclusion of the patient’s voice in the risk-benefit assessment of therapies.

However, no standards exist on how to analyse, interpret or report health-related quality of life (HRQOL) and other patient-reported outcomes (PROs).

This initiative wants to pursue efforts in addressing the urgent need for standardization, by setting clear and validated standards that are tailored to and endorsed by all relevant stakeholders.

With a strong international and multi-stakeholder Consortium, the initiative aims at finding consensus on suitable methods to analyse valid PRO objectives in cancer randomized clinical trials (RCTs) and ways to communicate these PRO findings in a standardized way that is understandable to all.

To achieve this aim, SISAQOL-IMI will identify valid PRO research objectives and match these with appropriate statistical methods for PRO analysis in cancer RCTs. Translation to the estimands framework will be provided. Furthermore, the possibility of extending these recommendations to single-arm trial designs will be explored.

Recommendations on clinically meaningful change for PRO instruments, as well as design considerations and ways for assessing quality of collected PRO data will be developed, and tools and templates for presentation and visualization of PRO findings freely made available. Strong emphasis is put on continuous collaboration with patient advocacy representatives throughout the project.

Increased interpretability, adoption and full use of PRO outcomes for all stakeholders is expected by providing consensus-based and validated recommendations and communication tools for PRO data, ultimately resulting in better communication and shared decision making, improved outcomes, treatment satisfaction and care.

All Grantees

Consorcio Mar Parc de Salut de Barcelona; Academisch Ziekenhuis Leiden; Region Hovedstaden; Pfizer Limited; Adelphi Values Ltd; Abbvie Inc; Statens Legemiddelverk; European Society for Medical Oncology; Klinicki Bolnicki Centar Rijeka; Universiteit Gent; European Organisation for Research and Treatment of Cancer Aisbl; The University of Birmingham; Oslo Universitetssykehus Hf; Stiftung Fur Qualitat Und Wirtschaftlichkeit Im Gesundheitswesen; Myeloma Patients Europe Aisbl; University of Leeds; Modus Outcomes Sas; Merck Kommanditgesellschaft Auf Aktien; Johns Hopkins University; Medizinische Universitat Innsbruck; Fundacion Publica Miguel Servet; The University of Sydney; Stichting Amsterdam Umc; Boehringer Ingelheim Internationalgmbh; The Critical Path Institute (C-Path) Non Profit Corporation; National Cancer Center; Bayer Aktiengesellschaft; Critical Path Institute Stichting; Queen's University At Kingston; Universitaetsklinikum Freiburg; Katholieke Universiteit Leuven; Esd - Evaluation Software Development Gmbh; The European Medicines Agency; University Health Network

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant